Losartan Pottasium

Losartan lowers blood pressure and protects the kidneys, but the evidence for it comes from studies with real limits: small samples, short follow-up, and manufacturer funding.

The largest trial here, the LIFE study of 9,193 patients, was funded by Merck, the company that makes losartan [3]. It found that losartan reduced new-onset atrial fibrillation compared to atenolol (6.8 vs 10.1 per 1,000 person-years, hazard ratio 0.67) and cut stroke risk in those who developed AF (HR 0.49) [3]. That is a real benefit. But the comparison drug was atenolol, not placebo, so the question is whether losartan is better than an older beta-blocker, not whether it is safe or effective in absolute terms.

The RENAAL trial, also Merck-funded, followed 1,513 type 2 diabetics with nephropathy for about 3.4 years [7]. Losartan reduced the composite of doubling creatinine or kidney failure by about 21% [7]. That same analysis showed losartan raises serum potassium: 38.4% of losartan patients hit potassium ≥5.0 at month 6, and higher potassium was linked to worse kidney outcomes (HR 1.22) [7]. The authors adjusted for potassium and claimed the renoprotective effect was actually larger, but that is a post-hoc statistical maneuver, not a clean finding.

The one-year open-label study of 199 patients showed blood pressure dropped from 164/102 to 137/89 mmHg, and vasoconstriction fell sharply [1, 2]. No control group, no blinding, no adverse event reporting. That is a before-after observation, not proof of safety.

The in vitro study comparing six antihypertensives found losartan caused no significant DNA damage in human lymphocytes, unlike captopril and enalapril [8]. That is reassuring at the cellular level, but it is not a long-term safety study.

What is missing: no trial compared losartan to a true placebo for hard outcomes like death or heart attack in the general hypertensive population. The OPTIMAAL trial in post-heart-attack patients found losartan trended toward higher mortality than captopril [4, 6]. The ELITE II trial in heart failure found the same trend [6]. Losartan is better tolerated than ACE inhibitors (fewer cough, less discontinuation) [5], but tolerability is not the same as efficacy.

My call: losartan is a reasonable blood pressure drug with documented kidney protection in diabetics, but the evidence base is industry-funded, the potassium risk is real, and the mortality data against ACE inhibitors is not favorable. Confidence: moderate.